Bis(9)-(-)-nor-meptazinol as a novel dual-binding AChEI potently ameliorates scopolamine-induced cognitive deficits in mice

Pharmacology Biochemistry and Behavior

Volumn 104, Issue 1, 2013, Pages 138-143

  Liu, Ting ^a,d   Xia, Zheng ^a   Zhang, Wei Wei ^a   Xu, Jian Rong ^a   Ge, Xin Xing ^a   Li, Juan ^a   Cui, Yongyao ^a   Qiu, Zhui Bai ^b   Xu, Jun ^c   Xie, Qiong ^b   Wang, Hao ^a   Chen, Hong Zhuan ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b FUDAN UNIVERSITY   (China)

^c SUN YAT SEN UNIVERSITY   (China)

^d SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Bis Mep; Cognitive amelioration; Dual binding AChE inhibitor; MTDL

Indexed keywords

ACETYLCHOLINESTERASE; AMYLOID BETA PROTEIN; BIS(9) NOR MEPTAZINOL; CHOLINESTERASE; CHOLINESTERASE INHIBITOR; HUPERZINE A; SCOPOLAMINE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CATALYSIS; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; DOSE RESPONSE; DRUG BINDING; DRUG EFFICACY; ENZYME INHIBITION; FEMALE; KINETICS; MALE; MOLECULAR DOCKING; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ACETYLCHOLINESTERASE; ALKALOIDS; ALZHEIMER DISEASE; ANIMALS; BRAIN; CHOLINESTERASE INHIBITORS; COGNITION; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; KINETICS; MALE; MAZE LEARNING; MEMORY DISORDERS; MEPTAZINOL; MICE; MODELS, MOLECULAR; NOOTROPIC AGENTS; SCOPOLAMINE HYDROBROMIDE; SESQUITERPENES;

ELECTROPHORUS ELECTRICUS; MUS;

EID: 84873722112     PISSN: 00913057     EISSN: 18735177     Source Type: Journal    
DOI: 10.1016/j.pbb.2012.11.009     Document Type: Article

References (31)

1. M. Bartolini, C. Bertucci, V. Cavrini, and V. Andrisano beta-Amyloid aggregation induced by human acetylcholinesterase: inhibition studies Biochem Pharmacol 65 2003 407 416
2. C. Bejar, R.H. Wang, and M. Weinstock Effect of rivastigmine on scopolamine-induced memory impairment in rats Eur J Pharmacol 383 1999 231 240
3. Y. Bourne, P. Taylor, Z. Radic, and P. Marchot Structural insights into ligand interactions at the acetylcholinesterase peripheral anionic site EMBO J 22 2003 1 12
4. J.J. Buccafusco, A.V. Terry Jr., S.J. Webster, D. Martin, E.J. Hohnadel, and K.A. Bouchard The scopolamine-reversal paradigm in rats and monkeys: the importance of computer-assisted operant-conditioning memory tasks for screening drug candidates Psychopharmacology (Berl) 199 2008 481 494
5. A. Castro, and A. Martinez Targeting beta-amyloid pathogenesis through acetylcholinesterase inhibitors Curr Pharm Des 12 2006 4377 4387
6. A. Cavalli, M.L. Bolognesi, A. Minarini, M. Rosini, V. Tumiatti, and M. Recanatini Multi-target-directed ligands to combat neurodegenerative diseases J Med Chem 51 2008 347 372
7. Y. Chen, E. Shohami, S. Constantini, and M. Weinstock Rivastigmine, a brain-selective acetylcholinesterase inhibitor, ameliorates cognitive and motor deficits induced by closed-head injury in the mouse J Neurotrauma 15 1998 231 237
8. N. de Bruin, and B. Pouzet Beneficial effects of galantamine on performance in the object recognition task in Swiss mice: deficits induced by scopolamine and by prolonging the retention interval Pharmacol Biochem Behav 85 2006 253 260
9. D.M. Du, and P.R. Carlier Development of bivalent acetylcholinesterase inhibitors as potential therapeutic drugs for Alzheimer's disease Curr Pharm Des 10 2004 3141 3156
10. J.M. Ellis Cholinesterase inhibitors in the treatment of dementia J Am Osteopath Assoc 1053 2005 145 158
11. G.L. Ellman, K.D. Courtney, V. Andres Jr., and R.M. Featherstone A new and rapid colormetric determination of acetylcholinesterase activity Biochem Pharmacol 7 1961 88 95
12. M.R. Farlow, S. Salloway, P.N. Tariot, J. Yardley, M.L. Moline, and Q. Wang Effectiveness and tolerability of high-dose (23 mg/d) versus standard-dose (10 mg/d) donepezil in moderate to severe Alzheimer's disease: a 24-week, randomized, double-blind study Clin Ther 32 2010 1234 1251
13. L.A. Frölich Review of the first transdermal treatment for Alzheimer's disease - the Rivastigmine patch Eur Neurol Rev 1 2008 33 35
14. X.X. Ge, X.L. Wang, P. Jiang, Y. Xie, T. Jiang, and Z.X. Rong Determination of Bis(9)-(-)-Meptazinol, a bis-ligand for Alzheimer's disease, in rat plasma by liquid chromatography-tandem mass spectrometry: application to pharmacokinetics study J Chromatogr 881 2012 126 130
15. H.M. Greenblatt, C. Guillou, D. Guénard, A. Argaman, S. Botti, and B. Badet The complex of a bivalent derivative of galanthamine with torpedo acetylcholinesterase displays drastic deformation of the active-site gorge: implications for structure-based drug design J Am Chem Soc 126 2004 15405 15411
16. G. Kryger, I. Silman, and J.L. Sussman Structure of acetylcholinesterase complexed with E2020 (Aricept): implications for the design of new anti-Alzheimer drugs Structure 7 1999 297 307
17. L.H. Lee, D.W. Shineman, and H.M. Fillit A diverse portfolio of novel drug discovery efforts for Alzheimer's disease: meeting report from the 11th International Conference on Alzheimer's Drug Discovery Alzheimers Res Ther 2 2010 33 36
18. F. Massoud, and S. Gauthier Update on the pharmacological treatment of Alzheimer's disease Curr Neuropharmacol 8 2010 69 80
19. D. Muñoz-Torrero Acetylcholinesterase inhibitors as disease-modifying therapies for Alzheimer's disease Curr Med Chem 15 2008 2433 2455
20. H. Ogura, T. Kosasa, Y. Kuriya, and Y. Yamanishi Donepezil, a centrally acting acetylcholinesterase inhibitor, alleviates learning deficits in hypocholinergic models in rats Methods Find Exp Clin Pharmacol 22 2000 89 95
21. E.H. Rydberg, B. Brumshtein, H.M. Greenblatt, D.M. Wong, D. Shaya, and L.D. Williams Complexes of alkylenelinked tacrine dimers with Torpedo californica acetylcholinesterase: binding of bis(5)-tacrine produces a dramatic rearrangement in the active-site gorge J Med Chem 49 2006 5491 5500
22. Z.Q. Shi, Q.Z. Zhang, and X.G. Jiang Pharmacokinetic behavior in plasma, cerebrospinal fluid and cerebral cortex after intranasal administration of hydrochloride meptazinol Life Sci 77 2005 2574 2583
23. G.M. Shutske, F.A. Pierrat, K.J. Kapples, M.L. Cornfeldt, M.R. Szewczak, and F.P. Huger 9-Amino-1,2,3,4-tetrahydroacridin-1-ols:synthesis and evaluation as potential Alzheimer's disease therapeutics J Med Chem 32 1989 1805 1813
24. D.H. Small Acetylcholinesterase inhibitors for the treatment of dementia in Alzheimer's disease: do we need new inhibitors Expert Opin Emerg Drugs 10 2005 817 825
25. A.V. Terry Jr., and J.J. Buccafusco The cholinergic hypothesis of age and Alzheimer's disease-related cognitive deficits: recent challenges and their implications for novel drug development J Pharmacol Exp Ther 306 2003 821 827
26. N. Tsuno Donepezil in the treatment of patients with Alzheimer's disease Expert Rev Neurother 9 2009 591 598
27. D.M. Walsh, and D.J. Selkoe Deciphering the molecular basis of memory failure in Alzheimer's disease Neuron 44 2004 181 193
28. H. Wang, P.R. Carlie, W.L. Ho, N.T. Lee, Y.P. Pang, and Y.F. Han Attenuation of scopolamine-induced deficits in navigational memory performance in rats by bis(7)-tacrine,a novel dimeric AChE inhibitor Zhongguo Yao Li Xue Bao 20 1999 211 217
29. Q. Xie, H. Wang, Zh Xia, M.Y. Liu, X. Wang, and W. Fu Bis-(-)-nor-meptazinols as novel nanomolar cholinesterase inhibitors with high inhibitory potency on Amyloid-β aggregation J Med Chem 51 2008 2027 2036
30. Z.Q. Xiong, X.C. Tang, J.L. Lin, and D.Y. Zhu Effects of isovanihuperzine A on cholinesterase and scopolamine-induced memory impairment Zhongguo Yao Li Xue Bao 16 1995 21 25
31. W.W. Zhang, M.K. Song, Y.Y. Cui, H. Wang, L. Zhu, and Y.Y. Niu Differential neuropsychopharmacological influences of naturally occurring tropane alkaloids anisodamine versus scopolamine Neurosci Lett 443 2008 241 245